https://pharmadevicenews.com/mirums-atebrioz-reduced-abnormal-bone-volume-in-young-children-but-will-the-fda-expand-its-approval/ PharmaDeviceNews en 2026-10-27T04:55:26+00:00 Mirum’s ATEBRIOZ reduced abnormal bone volume in young children, but will the FDA expand its approval? Atebrioz, Incyte, Ipsen, Mirum Pharmaceuticals, palovarotene, Pasatru, PROGRESS, Regeneron Pharmaceuticals, Sohonos, United States Food and Drug Administration, University of Pennsylvania, zilurgisertib https://pharmadevicenews.com/wp-content/uploads/2026/06/Mirum-Pharmaceuticals-and-Incyte-strengthen-the-case-for-targeted-ALK2-inhibition-in-FOP-e1781495975633.webp https://pharmadevicenews.com/aimedbios-991m-boehringer-ingelheim-cancer-deal-reaches-human-trials-but-can-bi-4060107-deliver/ PharmaDeviceNews en 2026-10-27T04:51:41+00:00 AimedBio’s $991m Boehringer Ingelheim cancer deal reaches human trials, but can BI 4060107 deliver? AimedBio, BI 4060107, Boehringer Ingelheim, P-ADC, Samsung Medical Center https://pharmadevicenews.com/wp-content/uploads/2026/07/Bio-Thera-tests-a-dual-action-CD25-ADC-against-advanced-solid-tumors-e1785126922532.webp https://pharmadevicenews.com/serp-01-gene-editing-results-support-phase-2-3-plans-for-inherited-lung-and-liver-disease/ PharmaDeviceNews en 2026-10-26T22:01:08+00:00 SERP-01 gene-editing results support Phase 2/3 plans for inherited lung and liver disease Boundless Bio, European Respiratory Society, Hannover Medical School, Renji Hospital, Serapha Bio, SERP-01, YolTech Therapeutics https://pharmadevicenews.com/wp-content/uploads/2026/10/Gene-editing-research-lab-e1793051707709.webp https://pharmadevicenews.com/orka-001-shows-strong-psoriasis-skin-clearance-results-as-pivotal-trials-approach-in-2027/ PharmaDeviceNews en 2026-10-26T21:24:08+00:00 ORKA-001 shows strong psoriasis skin-clearance results as pivotal trials approach in 2027 ORKA-001, ORKA-002, Oruka Therapeutics, University of Pennsylvania https://pharmadevicenews.com/wp-content/uploads/2026/10/Psoriasis-treatment-e1793049641354.webp https://pharmadevicenews.com/frontiers-fmc-376-triggered-responses-after-kras-inhibitor-failure-but-can-its-dual-state-mechanism-prevent-resistance/ PharmaDeviceNews en 2026-10-25T13:48:27+00:00 Frontier’s FMC-376 triggered responses after KRAS inhibitor failure, but can its dual-state mechanism prevent resistance? Adagrasib, European Society for Medical Oncology, FMC-376, Frontier Medicines, Keytruda, KRAS G12C, KRAZATI, LUMAKRAS, Marcelo Negrao, MD Anderson Cancer Center, pembrolizumab, PROSPER, sotorasib https://pharmadevicenews.com/wp-content/uploads/2026/06/Guardant360-CDx-FDA-approval-strengthens-the-liquid-biopsy-case-in-HER2-mutant-lung-cancer-e1781185177103.webp https://pharmadevicenews.com/beone-medicines-reports-new-phase-1-results-across-three-liver-and-lung-cancer-programmes/ PharmaDeviceNews en 2026-10-25T13:45:30+00:00 BeOne Medicines reports new Phase 1 results across three liver and lung cancer programmes BeOne Medicines, BG-C477, BGB-58067, BGB-B2033, European Society for Medical Oncology, KANDELA-302, Tevimbra, tislelizumab https://pharmadevicenews.com/wp-content/uploads/2026/09/ChatGPT-Image-Sep-17-2026-09_15_56-AM-e1789616803290.webp